88 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27692854	100	N-Arylsulfonyl-a-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity.	Boehringer Ingelheim Pharmaceuticals
26631321	37	Discovery and synthesis of cyclohexenyl derivatives as modulators of CC chemokine receptor 2 activity.	Bristol-Myers Squibb
25766632	31	Synthesis and biological evaluation of spirocyclic antagonists of CCR2 (chemokine CC receptor subtype 2).	Westf£Lische Wilhelms-Universit£T M£Nster
25893046	77	Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5.	Bristol-Myers Squibb
25666912	39	When structure-affinity relationships meet structure-kinetics relationships: 3-((Inden-1-yl)amino)-1-isopropyl-cyclopentane-1-carboxamides as CCR2 antagonists.	Leiden University
25453791	5	Design and synthesis of novel small molecule CCR2 antagonists: evaluation of 4-aminopiperidine derivatives.	TBA
24685539	44	The discovery and SAR of cyclopenta[b]furans as inhibitors of CCR2.	Janssen Research And Development
24613378	33	Alkylsulfone-containing trisubstituted cyclohexanes as potent and bioavailable chemokine receptor 2 (CCR2) antagonists.	Bristol-Myers Squibb
23916257	54	Discovery and SAR of 5-aminooctahydrocyclopentapyrrole-3a-carboxamides as potent CCR2 antagonists.	Janssen Research And Development
24900633	11	Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors.	Amgen
24900677	8	Targeting CCR2 Receptor To Treat Inflammation Diseases and Disorders.	Therachem Research Medilab (India)
23294701	49	A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists.	Janssen Research And Development
23182090	92	Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists.	Janssen Research And Development
20493592	25	Validated QSAR analysis of some diaryl substituted pyrazoles as CCR2 inhibitors by various linear and nonlinear multivariate chemometrics methods.	Tehran University Of Medical Sciences
20627722	89	Identification of a sulfonamide series of CCR2 antagonists.	Glaxosmithkline
23079519	86	In vivo activity of an azole series of CCR2 antagonists.	Glaxosmithkline
24900425	72	Discovery of a 4-Azetidinyl-1-thiazoyl-cyclohexane CCR2 Antagonist as a Development Candidate.	TBA
23075267	85	Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis.	Bristol-Myers Squibb
22931505	69	Chemokine receptor antagonists.	National Heart And Lung Institute
22939233	23	Benzimidazoles as benzamide replacements within cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists.	Bristol-Myers Squibb
22608963	109	The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity.	Astrazeneca
24900280	81	Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.	TBA
22475558	82	Discovery of an orally-bioavailable CC Chemokine Receptor 2 antagonist derived from an acyclic diaminoalcohol backbone.	Bristol-Myers Squibb
18487045	35	Substituted dipiperidine alcohols as potent CCR2 antagonists.	Johnson & Johnson Pharmaceutical Research And Development
18313297	107	Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series.	Deltagen Research Laboratories (Former Combichem)
18215519	4	Conformational studies of 3-amino-1-alkyl-cyclopentane carboxamide CCR2 antagonists leading to new spirocyclic antagonists.	Merck Research Laboratories
18232650	35	Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists.	TBA
17046269	86	Design and synthesis of Rho kinase inhibitors (II).	Kirin Brewery
16821774	86	Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.	Ono Pharmaceutical
16198561	99	Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.	Novartis Institutes For Biomedical Research
11931608	17	Inhibition of protein-protein association by small molecules: approaches and progress.	Pfizer
24900329	49	Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist.	TBA
22225639	29	Synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamide-derived antagonists of CC chemokine receptor 2 (CCR2).	Bristol-Myers Squibb
22061641	49	The discovery of novel cyclohexylamide CCR2 antagonists.	Johnson & Johnson Pharmaceutical Research And Development
22047688	51	CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole blood.	Glaxosmithkline
21940167	12	Design and synthesis of a library of chemokine antagonists.	Novartis Institutes Of Biomedical Research
21917454	159	Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.	Johnson & Johnson Pharmaceutical Research And Development
21783361	90	Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.	Johnson & Johnson Pharmaceutical Research And Development
21315584	74	Discovery of ((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxy-tetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(5-(trifluoromethyl)pyridazin-3-yl)piperazin-1-yl)methanone, PF-4254196, a CCR2 antagonist with an improved cardiovascular profile.	Pfizer
21341682	37	Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.	Telik
21316220	34	Design and synthesis of novel CCR2 antagonists: investigation of non-aryl/heteroaryl binding motifs.	Pfizer
21295478	81	Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist.	Incyte
21036044	43	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.	Incyte
20346664	27	gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists.	Bristol-Myers Squibb
20297846	33	Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.	Genzyme
20223662	174	Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.	Yangji Chemicals
19674898	31	Spiropiperidine CCR5 antagonists.	Roche Palo Alto
19481449	51	Novel sulfone-containing di- and trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.	Bristol-Myers Squibb
19237282	47	Design, synthesis, and structure-activity relationship of novel CCR2 antagonists.	Merck Research Laboratories
19131247	42	Discovery of trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.	Bristol-Myers Squibb
19014885	32	Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.	Roche Palo Alto
18990568	15	Synthesis and structure-activity relationship of 7-azaindole piperidine derivatives as CCR2 antagonists.	Johnson & Johnson Pharmaceutical Research And Development
18722120	42	Synthesis and evaluation of cis-3,4-disubstituted piperidines as potent CC chemokine receptor 2 (CCR2) antagonists.	Bristol-Myers Squibb
17715128	6	Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers.	Université
18258426	47	QSAR studies on CCR2 antagonists with chiral sensitive hologram descriptors.	National Institute Of Pharmaceutical Education And Research (Niper)
18226895	29	Probing the structural and topological requirements for CCR2 antagonism: holographic QSAR for indolopiperidine derivatives.	National Institute Of Pharmaceutical Education And Research (Niper)
18164199	34	Potent heteroarylpiperidine and carboxyphenylpiperidine 1-alkyl-cyclopentane carboxamide CCR2 antagonists.	Merck Research Laboratories
17929797	34	Synthesis, structure-activity relationship and in vivo antiinflammatory efficacy of substituted dipiperidines as CCR2 antagonists.	Johnson & Johnson Pharmaceutical Research And Development
17869105	42	Synthesis and biological evaluation of phenyl piperidine derivatives as CCR2 antagonists.	Johnson & Johnson Pharmaceutical Research And Development
17720492	107	Capped diaminopropionamide-glycine dipeptides are inhibitors of CC chemokine receptor 2 (CCR2).	Bristol-Myers Squibb
17587570	34	Potent and selective CC-chemokine receptor-2 (CCR2) antagonists as a potential treatment for asthma.	Johnson & Johnson Pharmaceutical Research And Development
17482462	60	3-Amino-1-alkyl-cyclopentane carboxamides as small molecule antagonists of the human and murine CC chemokine receptor 2.	Merck Research Laboratories
17461566	11	Discovery of 3-piperidinyl-1-cyclopentanecarboxamide as a novel scaffold for highly potent CC chemokine receptor 2 antagonists.	Merck Research Laboratories
17092717	59	Alpha-aminothiazole-gamma-aminobutanoic amides as potent, small molecule CCR2 receptor antagonists.	Merck Research Laboratories
17088058	40	Diaryl substituted pyrazoles as potent CCR2 receptor antagonists.	Merck Research Laboratories
17084087	36	Design and synthesis of rho kinase inhibitors (III).	Kirin Brewery
16884289	26	Novel, orally bioavailable gamma-aminoamide CC chemokine receptor 2 (CCR2) antagonists.	Merck Research Laboratories
16870431	54	4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties.	Merck Research Laboratories
16698264	37	Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.	Merck Research Laboratories
16539392	29	Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.	Takeda Pharmaceutical
15863339	29	Identification of chemokine receptor CCR4 antagonist.	Bristol-Myers Squibb Pharmaceutical Research Institute
15771462	125	Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.	Pharmaceutical Research Institute
15454236	36	Small molecule antagonists of the CCR2b receptor. Part 2: Discovery process and initial structure-activity relationships of diamine derivatives.	Deltagen Research Laboratories
15454235	29	Small molecule inhibitors of the CCR2b receptor. Part 1: Discovery and optimization of homopiperazine derivatives.	Institute For Bio-Medical Research
14698169	53	N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor.	Astrazeneca
12954060	4	CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach.	Glaxosmithkline
11720852	51	Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.	Merck Research Laboratories
11720851	52	Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.	Merck Research Laboratories
11514164	36	Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists.	Glaxosmithkline
11311066	76	Design, synthesis, and discovery of a novel CCR1 antagonist.	Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories
11206474	51	Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.	Merck Research Laboratories
10969972	39	CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound.	Smithkline Beecham Pharmaceuticals
10821717	29	Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.	Takeda Chemical Industries
18588282	63	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.	Johnson & Johnson Pharmaceutical